Remdesivir in Severe Cases of COVID-19 Infection

被引:0
|
作者
Boretti, Alberto [1 ]
机构
[1] Independent Sci, Wellington, New Zealand
关键词
Remdesivir; COVID-19; ARDS; severe ARDS; ICU care; virology;
D O I
10.2174/0122133372290992240409084133
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Background Assessing the efficacy of remdesivir for COVID-19 infection holds historical significance. Understanding its effectiveness from previous pandemic instances can enable us to gain insights into its efficacy, informing our strategies for responding to future outbreaks or variants.Objective Gaining an insight into the historical efficacy of remdesivir can offer valuable data for evaluating the advancement of COVID-19 treatments and the development of medical expertise in handling the disease.Methods The historical data regarding the effectiveness of remdesivir can enrich the pool of knowledge and evidence accessible for public health planning and decision-making. Understanding whether remdesivir was efficacious in previous instances may aid in comprehending its real-world impact on patient outcomes at those times. Such insights are crucial for evaluating treatment efficacy and refining strategies based on past experiences.Results In the late treatment of severe COVID-19 cases, which are particularly challenging, remdesivir has demonstrated a 6% improvement.Conclusion The 6% enhanced effect of remdesivir is not substantial, considering that it is an unweighted average of works with varying degrees of importance and reliability. Additionally, there are instances where conflicts of interest may have impacted the results. It is also possible that the observed improvement could be attributed to better patient care in certain environments.
引用
收藏
页码:273 / 278
页数:6
相关论文
共 50 条
  • [41] Remdesivir for Patients with COVID-19
    Augustin, M.
    Hallek, M.
    Nitschmann, S.
    [J]. INTERNIST, 2020, 61 (08): : 869 - 872
  • [42] Remdesivir bei COVID-19
    Dirk Einecke
    [J]. MMW - Fortschritte der Medizin, 2021, 163 (15) : 64 - 64
  • [43] Remdesivir for the treatment of COVID-19
    Ansems, Kelly
    Grundeis, Felicitas
    Dahms, Karolina
    Mikolajewska, Agata
    Thieme, Volker
    Piechotta, Vanessa
    Metzendorf, Maria-Inti
    Stegemann, Miriam
    Benstoem, Carina
    Fichtner, Falk
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (08):
  • [44] Efficacy of Remdesivir for COVID-19
    Zhang, Hongming
    Chen, Jibei
    Wang, Xiyong
    Chen, Baoan
    [J]. DISCOVERY MEDICINE, 2021, 31 (163) : 57 - 60
  • [45] Remdesivir: A Review in COVID-19
    Hannah A. Blair
    [J]. Drugs, 2023, 83 : 1215 - 1237
  • [46] Remdesivir for the Treatment of COVID-19
    Allen, Robert
    Turner, Matthew
    DeSouza, Ian S.
    [J]. AMERICAN FAMILY PHYSICIAN, 2022, 105 (02) : 131 - 132
  • [47] REMDESIVIR IN THE TREATMENT OF COVID-19
    Rosenberg, Karen
    [J]. AMERICAN JOURNAL OF NURSING, 2021, 121 (01) : 55 - 55
  • [48] Remdesivir and COVID-19 Reply
    Wang, Yeming
    Gu, Xiaoying
    Xu, Jiuyang
    Cao, Bin
    Wang, Chen
    [J]. LANCET, 2020, 396 (10256): : 954 - 954
  • [49] Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience
    Lee, Stephen
    Santarelli, Anthony
    Caine, Kristen
    Schritter, Sarah
    Dietrich, Tyson
    Ashurst, John
    [J]. JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2020, 120 (12): : 926 - 933
  • [50] Predictors for Severe COVID-19 Infection
    Bhargava, Ashish
    Fukushima, Elisa Akagi
    Levine, Miriam
    Zhao, Wei
    Tanveer, Farah
    Szpunar, Susanna M.
    Saravolatz, Louis
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (08) : 1962 - 1968